We have previously shown that hemopoietic stem cell transplant (HSCT) recipients can be stratified on day þ 7 as having low, intermediate or a high risk of transplantrelated mortality (TRM). With the aim of reducing TRM and GVHD, intermediate and high-risk patients (n ¼ 170) were randomized to receive anti-thymocyte globulin (ATG, thymoglobuline) on day þ 7 (n ¼ 84) or no treatment (n ¼ 86) (controls). There was a reduction of TRM from 35% in controls to 29% in ATG patients (P ¼ 0.3), of acute GVHD III-IV from 15 to 5% (P ¼ 0.02) and of chronic GVHD from 26 to 11% (P ¼ 0.03); survival was comparable. The predictive value of the day þ 7 score on TRM was confirmed for controls (19 vs 42% for intermediate vs high risk, respectively, P ¼ 0.03), whereas ATG abrogated this predictive effect (29 vs 29%). ATG reduced GVHD (P ¼ 0.006) in high-risk patients, but not in patients with an intermediate risk.
Introduction
Acute GVHD remains a significant clinical challenge for patients undergoing an allogeneic hemopoietic stem cell transplant (HSCT); 1 cellular events leading to acute GVHD, as described by Ferrara et al., 2 seem to occur very soon, perhaps within hours from the infusion of the graft containing mature donor T cells. Therefore, when clinical acute GVHD is diagnosed, the disease has been ongoing for many days at the cellular level, and the inflammatory cytokine cascade is fully activated. 2, 3 This being the case, it comes as no surprise that treatment of acute GVHD is rather unsuccessful and has made little or no progress in the past 30 years. 4 This is true for conventional immunosuppression with steroids and anti-thymocyte globulin (ATG), 5 as well as for MoABs directed against IL2 receptors, TNF or ABX, [6] [7] [8] [9] [10] with one recent exception: 11 it should be noted that in a recent CIBMTR (Center for International Blood and Marrow Transplant Research) trial, etanercept has not proven to be superior to mycophenolate, in combination with steroids (unpublished) .
We argued that intervention should be started before the clinical diagnosis of acute GVHD is made, in the form of pre-emptive treatment. However, one first needs to identify patients at risk of GVHD soon after transplant, and with this aim, we worked on a scoring system on day þ 7 after HSCT, first based on day þ 7 bilirubin and blood urea nitrogen. 12 These two laboratory tests identify patients with a significantly different risk of GVHD and transplantrelated mortality (TRM), as shown in our Unit of adult transplants and validated in a separate pediatric Unit using a different central lab. 12 The next step was to test whether an early intervention with immunosuppression was feasible and whether it would reduce severe acute GVHD: we ran a small pilot study with ATG 1.25 mg/kg 3 Â starting on day þ 7, in 18 high-risk patients, and compared the results with a historic group of 20 untreated high-risk patients (controls), and showed reduced acute GVHD in patients receiving the additional dose of ATG on day þ 7. 13 We were in the meantime refining the scoring system on day þ 7, and found other significant laboratory tests such as serum cholinesterase, total serum proteins and gamma glutamyl transferase:
14 the revised day þ 7 score identifies patients with a low risk (15%), an intermediate risk (40%) and a high risk of TRM (60%).
T-cell depletion, have been unable to show a reduction of early mortality when compared with that in unmanipulated transplants: this is mainly because of the fact that patients receiving more intense prophylaxis are at a higher risk of infections. 16 In other words, a reduction or abrogation of GVHD does not necessarily translate into reduced mortality.
In this study, we report a prospective randomized study of pre-emptive GVHD treatment with ATG in 170 patients with an intermediate/high-risk day þ 7 score: the primary end point of the study was TRM and the secondary end point was acute GVHD grade III-IV. Eligible for this trial were patients undergoing a transplant from unrelated or one Ag family mismatched donors.
Patients and methods

Patients
This is a prospective multicenter trial of the Gruppo Italiano Trapianti di Midollo Osseo (GITMO). Approval for the study was obtained from the ethics committee of the participating transplant centers. Informed consent was provided according to the Declaration of Helsinki, approved by the ethics committee and signed by the patients.
Patients were treated in seven GITMO Centres: Genova S Martino, Milano S Raffaele, Pescara, Roma S Camillo, Catania, Reggio Calabria and Taranto. Clinical details of patients are outlined in Table 1 , stratified by treatment group. The two groups were well balanced in terms of patients' age, HLA matching, disease, disease phase and intermediate/high-risk score on day þ 7.
Donors
A total of 25 were related donors with one Ag mismatch on class I or DRB1; 145 donors were unrelated and were selected through the Italian Bone Marrow Donor Registry (IBMDR). A total of 52 unrelated donors were 10/10 allele matched with their recipients, at the HLA A, B, C, DRB1, DQ alfa and DQ beta loci. One patient had an allele mismatch at DRB1, 13 had one or two alleles mismatched at DQ alfa and DQ beta and 104 had one or more allele or Ag mismatches at class I.
Transplant protocol
The conditioning regimen consisted of CY (120 mg/kg) and TBI 12 Gy in 98 (47 and 51 in the two randomization groups) patients and a reduced intensity regimen in 72 patients. The latter was a combination of thiotepa 10 mg/kg and CY 100 mg/kg. All patients received rabbit ATG (Thymoglobulin, Genzyme, Boston, MA, USA) 3.75 mg/kg as a slow i.v. drip on days -3 and -2 (total dose 7.5 mg/kg). All patients received CsA 1 mg/kg i.v. from day À7, and MTX 15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3, þ 6 and þ 11. Thus, all patients received CYA and ATG pretransplant and CYA þ MTX post transplant. The i.v. CYA administration was continued until day þ 20, or until patients could swallow, and then it was switched to oral CYA 5-10 mg/kg per day in two divided doses, and continued for at least 5 months, at which time, in the absence of chronic GVHD, CYA would be tapered and discontinued.
Day þ 7 score All patients were scored on day þ 7, using day þ 7 serum cholinesterase, gamma glutamyl transferase, total serum proteins and blood urea nitrogen as described.
14 They were eligible for randomization if they scored as intermediate or high risk.
Randomization procedures
Patients signed an informed consent before the transplant, and were instructed that on day þ 7, they would be eligible for randomization to an additional dose of ATG. On day þ 7, patients were randomized after stratification for risk score (intermediate/high), disease phase (early/advanced), age (o/X35 years) and donor type (family mismatched or unrelated). Control patients received no further treatment on day þ 7. Patients randomized to ATG received 1.25 mg/ kg i.v. on days þ 7, þ 9 and þ 11 (total dose 3.75 mg/kg). After the first 20 patients were randomized, because of the absence of acute GVHD III-IV in the day þ 7 ATG group and because of the occurrence of two EBV reactivations, the third dose of ATG was stopped. The next 150 patients were randomized to control or to 1.25 mg/kg of ATG on days þ 7 and þ 9. Pre-emptive treatment of acute GVHD A Bacigalupo et al
End points and statistical analysis
The primary end point of the study was TRM and the secondary end point was acute GVHD grade III-IV. Univariate and multivariate COX analyses were carried out on TRM and survival. Cumulative incidence curves were constructed for TRM. Actuarial curves were used for OS.
Results
Primary end point: TRM and ATG
The overall cumulative incidence of TRM is depicted in Figure 1 : it was 29 and 35 % for patients receiving or not receiving ATG on day þ 7, respectively (P ¼ 0.3). We then looked at the effect of day þ 7 ATG in different patient strata (Figure 2 ): the risk plots show that ATG given on day þ 7 (ATG day þ 7) may be beneficial in patients with a high day þ 7 score, with an HLA-mismatched donor, especially if mismatched, related, and in male grafted from female donors. In other patient strata, ATG day þ 7 has either no effect or a trend for a detrimental effect, such as for intermediate-risk patients. The risk plots show that ATG day þ 7 had no significant effect overall on TRM ( Figure 2 ).
Graft-vs-host disease
Acute GVHD grade III-IV was overall reduced from 15% (controls) to 5% (day þ 7 ATG) (P ¼ 0.02) and chronic GVHD from 27 to 11% (P ¼ 0.03) ( Figure 3 ). As shown in Figure 4 , the risk plots suggest an effect of ATG day þ 7 on GVHD in patients with a high risk on day þ 7, whereas it had no effect in patients with an intermediate risk; the plots also show a greater effect in patients with advanced disease. Overall, there was a significant reduction of acute GVHD grade III-IV, with a risk of 0.28 (P ¼ 0.03) for patients receiving ATG on day þ 7 (Figure 4 ).
Day þ 7 risk score and TRM In control patients (no ATG on day þ 7), the risk score on day þ 7 confirmed to be a significant predictor of TRM (19% for intermediate and 42% for high risk, P ¼ 0.02). This was no longer true in the ATG day þ 7 group (29 vs 29%, respectively, P ¼ 0.8) ( Figure 5 ).
Univariate and multivariate analysis
In univariate analysis, predictors of TRM were disease phase (P ¼ 0.09) and day 7 risk score (P ¼ 0.05) ( Table 2 ). In multivariate analysis on TRM, disease phase (P ¼ 0.02) was significantly predictive, whereas the day þ 7 risk score (P ¼ 0.06) and donor/recipient gender mismatch (P ¼ 0.08) had a borderline effect ( Table 2 ). The same variables were also predictive of survival ( Table 2) . Table 3 outlines the causes of death in controls and patients given ATG on day þ 7, respectively: 41 and 43%
Causes of death
survive, 24 and 28% died of relapse-related complications and 35 and 29% died of transplant-related complications (TRM). Acute and chronic GVHD accounted, respectively, for nine (10%) and four deaths (5%) ( Table 3) . Infections and other causes of death, such as multiorgan failure, were equally distributed in the two groups. The actuarial survival of the two groups of patients was comparable ( Figure 6 ).
Infections
Of the 170 patients, 19 died of infectious complications, 11 in the control and 8 in the day þ 7 ATG groups. Of these, six were because of EBV-related lymphoproliferative diseases, four in the ATG day þ 7 and two in control groups (Table 3 ). Seven were because of bacterial infections, two were because of invasive fungal infections and four were of unknown etiology.
CMV and EBV reactivation
Of 132 patients for whom CMV and EBV weekly monitoring was available, the rate of CMV reactivation was 51% for controls and 49% for ATG day þ 7 patients. Mortality was similar in patients with or without CMV reactivation (34 vs 32%, respectively). EBV reactivation was recorded in 67% of controls and in 68% of ATG day þ 7 patients: eight and six patients, respectively, had over 1000 EBV copies and were treated initially with cidofovir (three and four patients, respectively) and then with rituximab 375 mg/m 2 (five and two patients, respectively). Of the seven patients receiving first line cidofovir, five proceeded to develop a lymphoproliferative disorder and of the seven patients treated with rituximab first line, one developed a lymphoproliferative disease. Transplant controls Figure 4 Odds ratio plots of GVHD III-IV in different patient strata. Anti-thymocyte globulin (ATG) given on day þ 7 reduces GVHD in patients with a high risk on day þ 7 with advanced disease or with mismatched donors. Overall, the odds ratio (OR) of developing acute GVHD grade III-IV is reduced when ATG is given on day þ 7 (OR ¼ 0.28; P ¼ 0.03).
Pre-emptive treatment of acute GVHD A Bacigalupo et al mortality was 49 and 22%, respectively, in patients without or with EBV reactivation, and 25 vs 21%, respectively, if only patients alive on day þ 30 were considered.
Discussion
We have shown in this study that patients receiving a fixed dose of ATG pre-transplant have reduced acute GVHD grade III-IV if an additional dose of ATG is given on day þ 7 after an alternative donor HSCT. This was associated with a reduction of GVHD-related deaths and reduced extensive chronic GVHD. However, TRM was not reduced overall and survival was comparable with patients receiving no additional dose of ATG. We have also confirmed that transplant mortality can be predicted on day þ 7 after transplant. With regard to the first point, acute GVHD has been shown to be reduced in alternative donor HSCT when ATG is added to the conditioning regimen; this is true for different brands of ATG and different ATG sources (horse, rabbit). [17] [18] [19] [20] [21] [22] The reduction of acute GVHD grade II-IV is in the order of 30%, and that of acute GVHD grade III-IV, in the order of 20%, as reported in a review of a large number of retrospective studies. 23 There are only two Figure 5 The effect of the day þ 7 risk score on transplant-related mortality (TRM) in controls (left panel) and in patients randomized to anti-thymocyte globulin (ATG) on day þ 7 (right panel). The day þ 7 risk score predicts TRM in controls, but not in day þ 7 ATG patients.
Table 2
Univariate and multivariate COX analysis on TRM and survival
Univariate
Multivariate Pre-emptive treatment of acute GVHD A Bacigalupo et al prospective studies testing the addition of ATG to the conditioning regimen, compared with controls not receiving ATG; 16, 24 both confirm that acute GVHD can be reduced when ATG is added to the conditioning regimen or immediately after transplant. One of these studies 16 suggests that there may be a dose effect, such that a higher dose of ATG results in a greater protective effect. A subsequent analysis revealed that both dose and timing of ATG are relevant for the protective effect of ATG on GVHD, and, after a step-down multivariate analysis, timing emerged as the most important variable. 25 Thus, a lower dose of ATG, given very close to transplant, may be more effective in preventing GVHD than a higher dose given 3 or 4 days before HSCT. Indeed, in vivo concentration of ATG has been shown to correlate with acute GVHD, and patients with serum levels of rabbit IgG 470 mg/ml before transplant had a significantly lower risk of GVHD. 26 In this study, we tested whether acute GVHD grade III-IV would be reduced in alternative donor transplants receiving 7.5 mg/kg of ATG pre-transplant and randomized to receive an additional dose of ATG 2.5 mg/kg on day þ 7. We showed that acute GVHD grade III-IV was reduced from 15% in controls to 5% in patients receiving ATG on day þ 7. The difference was statistically significant. We also showed that extensive chronic GVHD was reduced in day þ 7 ATG patients from 26 to 11%. Patients were stratified at randomization on the basis of a day þ 7 risk score, as previously described; 14 reduction of acute GVHD was significant in patients with a high risk, but not in patients with an intermediate day þ 7 risk.
Despite the reduction of acute and chronic GVHD in retrospective and prospective studies, there has been only a modest survival advantage for patients receiving ATG over controls. 23 One problem is that reduced acute GVHD is counterbalanced by increased infectious complications, and it takes perhaps a decade before reduced chronic GVHD improves survival. 27 Therefore, reducing GVHD does not mean that TRM will be reduced. This study is in keeping with these results, and shows that TRM is not significantly reduced overall in patients receiving an additional dose of ATG on day þ 7 compared with that in controls. Hence, once again, this is a trial with a reduced GVHD in the treatment arm, but with comparable TRM, although infectious deaths were not increased in the day þ 7 ATG arm, as in our previous study, 16 nor were other transplantrelated complications, such as multiorgan failure. We did see a high rate of EBV reactivation, with approximately 10% of patients requiring treatment with rituximab; lymphoproliferative disease was observed when cidofovir was given as first line therapy, whereas there was only one case in patients receiving rituximab as first line therapy. We believe that weekly monitoring for EBV is required in these patients receiving ATG before and/or after an alternative donor transplant, and treatment with rituximab is suggested when EBV copies exceed 1000; when appropriate monitoring and treatment are instituted, EBV reactivation has no significant impact on transplant mortality or survival. 28 The same can be said for CMV reactivation, which, in our center, has no effect on TRM or on survival. 28 When looking at the two risk groups on day þ 7, we could show that there was no effect of ATG on TRM in intermediate-risk patients (19 vs 29%, P ¼ 0.3), whereas there was a trend for a reduction of TRM in day þ 7 highrisk patients (42 vs 29%, P ¼ 0.1). One could hypothesize that additional immunosuppressive therapy would be beneficial only in patients at a high risk of GVHD and transplant complications; on the other hand, patients with an intermediate risk would not benefit from additional immunosuppression and could actually have a detrimental effect.
Finally, in a previous study, we had shown that TRM could be predicted by the day þ 7 risk score; 14 in this prospective study, the risk score proved predictive in control patients receiving standard conditioning regimen and ATG prevention, whereas it was no longer significant in patients receiving day þ 7 ATG. Therefore, when patients are left untreated, as in our previous study, 14 the day þ 7 risk score predicts transplant mortality; however, when early intervention is instituted post transplant, this may modify the clinical course and abrogate the effect of negative predictors. It should be said that TRM was reduced in this trial, when compared with our predictive study.
14 This may be the consequence of improved supportive care and improved donor/recipient matching, and may also have blunted the statistical power of the study because of a lower TRM in control patients.
In conclusion, we confirm that patients with a different risk of TRM can be identified on the basis of standard day þ 7 laboratory values after an alternative donor HSCT; in high-risk patients, the administration of ATG on day þ 7 reduces GVHD and shows a trend for reduced TRM, whereas there is no effect on intermediate-risk patients. These results may represent a platform for risk-adapted post transplant immune modulation.
